BofA lowered the firm’s price target on BioXcel Therapeutics to $7 from $8 and keeps a Buy rating on the shares after the company announced a Q4 update. With a cash runway into mid-2024, the firm notes that financing continues to be a risk and focus for investors and it is looking toward updates from management regarding future financing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- BioXcel Therapeutics provides updates on clinical programs for BXCL501
- BioXcel Therapeutics expects cash to fund operations through mid-2024
- BioXcel Therapeutics reports Q4 EPS (76c), consensus (91c)
- BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
